GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nectar Lifesciences Ltd (LUX:NECLF) » Definitions » Forward PE Ratio

Nectar Lifesciences (LUX:NECLF) Forward PE Ratio : 0.00 (As of Jun. 10, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Nectar Lifesciences Forward PE Ratio?

Nectar Lifesciences's Forward PE Ratio for today is 0.00.

Nectar Lifesciences's PE Ratio without NRI for today is 142.91.

Nectar Lifesciences's PE Ratio for today is 142.91.


Nectar Lifesciences Forward PE Ratio Historical Data

The historical data trend for Nectar Lifesciences's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nectar Lifesciences Forward PE Ratio Chart

Nectar Lifesciences Annual Data
Trend
Forward PE Ratio

Nectar Lifesciences Quarterly Data
Forward PE Ratio

Competitive Comparison of Nectar Lifesciences's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Nectar Lifesciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nectar Lifesciences's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nectar Lifesciences's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Nectar Lifesciences's Forward PE Ratio falls into.



Nectar Lifesciences Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Nectar Lifesciences  (LUX:NECLF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Nectar Lifesciences Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Nectar Lifesciences's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nectar Lifesciences (LUX:NECLF) Business Description

Traded in Other Exchanges
Address
SCO 38-39, Sector 9d, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009
Nectar Lifesciences Ltd is an India-based pharmaceutical company. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products, The company's product includes cefixime trihydrate, cefdinir, cefprozil, cefoxitin sodium, cefpirome sulphate, and others. Geographically, it derives a majority of its revenue from India.

Nectar Lifesciences (LUX:NECLF) Headlines

No Headlines